In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Provention Bio Inc (PRVB), with a price target of $8. The company’s shares closed on Friday at $2.75.
Selvaraju wrote:
“We value Provention Bio using a discounted cash flow (DCF)-based methodology, which ascribes a 70% probability of approval to PRV-031, a 50% probability of approval to 40% probability of approval to PRV-300. We do not currently assign value to any of the company’s other assets. A 15% discount rate and 2% terminal growth rate is applied, along with an effective tax rate of roughly 27%. We derive a total firm value of approximately $417M (vs. the prior $400M), which translates to a target price of $8.00 per share assuming 52M shares outstanding as of end-2019.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 0.9% and a 38.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Provention Bio Inc has an analyst consensus of Moderate Buy, with a price target consensus of $7.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8 and a one-year low of $1.52. Currently, Provention Bio Inc has an average volume of 36.49K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-300 for ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of T1D onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.
